Please login to the form below

Not currently logged in
Email:
Password:

dulaglutide

This page shows the latest dulaglutide news and features for those working in and with pharma, biotech and healthcare.

Lilly claims cluster headache first for CGRP drug Emgality

Lilly claims cluster headache first for CGRP drug Emgality

IL-23 inhibitor Skyrizi (risankizumab), and top-selling diabetes therapy Trulicity (dulaglutide) is also under pricing pressure.

Latest news

More from news
Approximately 2 fully matching, plus 43 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics